Intercure Asset Resilience Ratio
Intercure asset resilience ratio. Intercure (INCR) has an Asset Resilience Ratio of 0.03% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Intercure liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Intercure (2010–2025)
Asset resilience ratio of Intercure from 2010 to 2025. This chart shows how Intercure's Asset Resilience Ratio has changed over time. Read total liabilities of Intercure for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Intercure's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Intercure balance sheet assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA209.00K | 0.03% |
| Total Liquid Assets | ILA209.00K | 0.03% |
Asset Resilience Insights
- Limited Liquidity: Intercure maintains only 0.03% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Intercure Industry Peers by Asset Resilience Ratio
Compare Intercure's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 29.37% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shenzhen Chipscreen Biosciences Co
SHG:688321 |
Drug Manufacturers - Specialty & Generic | 5.10% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
HPGC Renmintongtai Pharmaceutical Corp
SHG:600829 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Intercure Asset Resilience Ratio by Year (2010–2025)
Intercure asset resilience ratio by year from 2010 to 2025. The table below shows the annual Asset Resilience Ratio data for Intercure.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.03% | ILA209.00K ≈ $560.32 |
ILA690.55 Million ≈ $1.85 Million |
-0.01pp |
| 2024-12-31 | 0.04% | ILA333.00K ≈ $892.76 |
ILA762.57 Million ≈ $2.04 Million |
+0.02pp |
| 2023-12-31 | 0.02% | ILA187.00K ≈ $501.34 |
ILA786.61 Million ≈ $2.11 Million |
+0.00pp |
| 2022-12-31 | 0.02% | ILA205.00K ≈ $549.60 |
ILA958.01 Million ≈ $2.57 Million |
-0.03pp |
| 2021-12-31 | 0.05% | ILA330.00K ≈ $884.72 |
ILA686.32 Million ≈ $1.84 Million |
-0.07pp |
| 2020-12-31 | 0.12% | ILA376.00K ≈ $1.01K |
ILA326.27 Million ≈ $874.72K |
+0.05pp |
| 2019-12-31 | 0.06% | ILA177.00K ≈ $474.53 |
ILA282.23 Million ≈ $756.66K |
-0.62pp |
| 2018-12-31 | 0.68% | ILA246.00K ≈ $659.52 |
ILA35.92 Million ≈ $96.30K |
-0.65pp |
| 2017-12-31 | 1.34% | ILA319.75K ≈ $857.25 |
ILA23.95 Million ≈ $64.20K |
-0.27pp |
| 2016-12-31 | 1.61% | ILA446.20K ≈ $1.20K |
ILA27.73 Million ≈ $74.35K |
-7.36pp |
| 2015-12-31 | 8.97% | ILA1.13 Million ≈ $3.04K |
ILA12.62 Million ≈ $33.84K |
-54.16pp |
| 2014-12-31 | 63.13% | ILA1.67 Million ≈ $4.47K |
ILA2.64 Million ≈ $7.08K |
+12.34pp |
| 2013-12-31 | 50.79% | ILA3.13 Million ≈ $8.39K |
ILA6.16 Million ≈ $16.53K |
-10.82pp |
| 2012-12-31 | 61.61% | ILA8.95 Million ≈ $24.00K |
ILA14.53 Million ≈ $38.95K |
+61.30pp |
| 2011-12-31 | 0.31% | ILA9.00K ≈ $24.13 |
ILA2.92 Million ≈ $7.83K |
-7.28pp |
| 2010-12-31 | 7.59% | ILA100.00K ≈ $268.10 |
ILA1.32 Million ≈ $3.53K |
-- |
About Intercure
InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in… Read more